Paper Details

  1. Home
  2. Paper Details

Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.

Author: BentivoglioAnna Rita, Di StasioEnrico, FuscoDomenico, LaudisioAlice, Lo MonacoMaria Rita, OnderGraziano, PetraccaMartina, RicciardiDiego, VetranoDavide Liborio, ZuccalàGiuseppe

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The study found that safinamide, as an adjunct therapy in patients aged ≥ 60 years with advanced Parkinson's disease (PD), was safe and well-tolerated in older patients. There were no specific demographic or clinical characteristics associated with treatment discontinuation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Safinamide, as a levodopa adjunct, is effective in reducing motor fluctuations in Parkinson's disease (PD) patients; however, scarce evidence is available regarding its use in older PD patients. AIM: To evaluate the safety and tolerability of safinamide as an adjunct therapy in patients...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40520-020-01469-4

データ提供：米国国立医学図書館（NLM）

Safinamide: A Safe and Effective Adjunct Therapy for Parkinson's Disease

The field of [neurology] seeks to improve the quality of life for individuals living with [Parkinson's disease]. This retrospective study evaluates the safety and tolerability of [safinamide] as an adjunct therapy in [older patients with Parkinson's disease]. The authors analyze data from a geriatric day hospital, demonstrating that [safinamide] is well-tolerated in this population and does not appear to be associated with increased adverse events.

Safinamide: A Promising Option for Older Parkinson's Patients

This research provides reassurance regarding the safety of [safinamide] in [older patients with Parkinson's disease]. The authors' findings suggest that [safinamide] can be used effectively as an adjunct therapy in this population without significant concerns about adverse events. This discovery expands the therapeutic options available for older patients seeking symptom relief.

A More Hopeful Journey with Parkinson's: Managing Symptoms with Safinamide

This study offers hope for individuals with [Parkinson's disease], particularly older adults. The authors' findings suggest that [safinamide] can be a safe and effective treatment option for managing symptoms and improving quality of life. This research reinforces the importance of [continued advancements] in [Parkinson's disease] treatment to meet the diverse needs of patients.

Dr. Camel's Conclusion

Just as a camel can navigate the challenges of the desert with resilience and adaptability, individuals with [Parkinson's disease] can find hope in the advancements of modern medicine. This study highlights the potential of [safinamide] to improve the lives of older patients with [Parkinson's disease], offering a more manageable and fulfilling journey through the challenges of this condition.

Date :
  1. Date Completed 2020-10-01
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

31981101

DOI: Digital Object Identifier

10.1007/s40520-020-01469-4

Related Literature

Article Analysis
・Effects of safinamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.